Takeda exits cell therapy research
Takeda will seek an external partner to leverage its cell therapy platform technologies
Takeda will seek an external partner to leverage its cell therapy platform technologies
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
The product will be manufactured at Lupin’s Chhatrapati Sambhajinagar facility in India
Subscribe To Our Newsletter & Stay Updated